Research Director at the Finlay Vaccine Institute (IFV), Dagmar Garcia, on Friday celebrated results of clinical trials of the Cuban Covid-19 vaccine Soberana Plus on the magazine The Lancet Respiratory Medicine.
 
This is undoubtedly the foreign publication with the highest impact during the Covid-19 pandemic, the expert said, and shared part of the text that shows how a single dose of the Finlay-FR-1A (Soberana Plus) vaccine against the SARS-CoV-2 coronavirus strengthened the preexisting natural immunity with an excellent security profile.
 
This publication, an authorized forum for key opinion leaders in Medicine have a 30.7 impact factor and is a reference in this subject, according to a previous report of this institute, creator of this vaccine.
 
Since last year, Cuba has administered the two-dose schedule of Soberana 02 ( also created in this institute) to part of its adult citizens and most of its pediatric population and a booster shot of Soberana Plus.
 
The latter also became the only vaccine of its kind in the world authorized in children older than 2 years of age recovering from Covid-19, this Cuban scientific institute reported.
 
The results of the trial with children who suffered from this disease showed security after the administration of a dose and the benefits against the potential risk of reinfection, it added.
 
Moreover, the clinical trial Soberana Plus Turin was carried out with this vaccine, devised to assess its effectiveness in Covid-19 convalescents and subjects who had not suffered from this disease but had been previously immunized with other products.